riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
First line treatment of patients with low grade B cell Non Hodgkin's lymphoma (NHL). Rituximab to be included in CD20 positive patients. 1
Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin's lymphoma (NHL). 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (+) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine